IL33 and steatosis: Indeed, treatment with recombinant IL-33 (rIL-33)-attenuated pathology in a mouse model of steatosis-related non-alcoholic fatty liver disease at the cost of increasing ST2-dependent fibrosis of the liver, thus indicating that IL-33 can have both protective and deleterious pro-fibrotic roles in regulating liver homeostasis [73, 83].